GRAIL, Inc. reported $165M of revenue over the trailing twelve months, +23% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $165M (to Q2 2026). Net income: −$392M, trailing twelve months to Q2 2026. Free cash flow: −$296M, trailing twelve months to Q2 2026. Operating margin: −338%, trailing twelve months to Q2 2026.

GRALGRAIL, Inc.

Healthcare

$140.55+255% 1Y

$140.55

$41.6552 weeks$153.92

GRAL as reported

GRAIL, Inc. reported $165M of revenue over the trailing twelve months, +23% on the year before. 8 reported series are charted on this page, each one as filed.

$165M

Revenue, trailing twelve months · to Q2 2026 · +23% against the twelve months before

Net income: −$392M
Net income · −12% year on year · trailing twelve months to Q2 2026
Free cash flow: −$296M
Free cash flow · −20% year on year · trailing twelve months to Q2 2026
Operating margin: −338%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for GRAL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$165M	+23%	Q2 2026
Net income	−$392M	−12%	Q2 2026
EPS	−$9.69	−20%	Q2 2026
Operating margin	−338%	n/a	Q2 2026
Net margin	−237%	n/a	Q2 2026
ROE	−16%	n/a	Q2 2026
ROA	−14%	n/a	Q2 2026
Free cash flow	−$296M	−20%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.